Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
about
Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal CancerFeasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping.Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancerDetection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array.In vitro validation of an ultra-sensitive scanning fluorescence microscope for analysis of circulating tumor cells.Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis.KRAS mutation testing in metastatic colorectal cancerRelationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis.High-performance size-based microdevice for the detection of circulating tumor cells from peripheral blood in rectal cancer patients.May CTC technologies promote better cancer management?The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer.Apoptosis Induction in Primary Human Colorectal Cancer Cell Lines and Retarded Tumor Growth in SCID Mice by Sulforaphane.Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancerComparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancerPart 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expressionDetection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer.KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancerComparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications.KRAS Testing: A Tool for the Implementation of Personalized Medicine.Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients.Development of a deregulating microRNA panel for the detection of early relapse in postoperative colorectal cancer patients.Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer.Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.Circulating Tumor Cells and Colorectal Cancer.Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer.Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis-capable malignancy.Cancer biomarker discovery: current status and future perspectives.Circulating tumor cells as promising novel biomarkers in solid cancers.Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer.Identification of differently expressed genes with specific SNP Loci for breast cancer by the integration of SNP and gene expression profiling analyses.Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2.Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?KRAS mutation screening by chip-based DNA hybridization--a further step towards personalized oncology.Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen.Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.Detection of circulating tumor cells: Clinical relevance of a novel metastatic tumor marker.Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications.Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma.
P2860
Q26738587-7D20D7FA-348B-4198-B19C-074F9AA99E91Q33620743-9794CC47-F25A-48FC-823B-1888B6688E81Q33631430-4ECE6279-8451-424C-B43B-BC827F71B65AQ33749696-EC2B40A5-2791-4F8C-9817-5D236250E40BQ34130345-0254E307-BA4B-4E5F-B36F-410E370AE51FQ34605970-1DE4E8FD-3D3D-40FE-A259-2DC09C3F8230Q34643960-46134804-5238-4005-A3DE-E9A9D4B68082Q34996408-D6B9755C-14D3-4862-AC1A-5F864044BBE8Q34997543-BBDF3B13-B3DA-4EC6-814A-B3FFDABD6528Q35016353-27B89C99-9188-4DF8-B204-B175D5785E2FQ35065408-874D971D-A377-4A78-8B6B-6B716B618DD0Q35116419-BC8AFCFB-ACAD-44B3-A1E8-398EE51C9445Q35392062-34D58704-EC63-4B0C-81EC-F526207C2409Q35576801-AA7D0680-BC8D-4C77-A9C2-7A2456ECF7D1Q35584647-0F263101-C8D7-4DE4-8A30-829F47EF1D59Q35882193-DE208B36-DEBA-4770-8A53-C83625DDB024Q36213034-7A5A3DDC-32BB-4ED0-93FC-14F02F242975Q36362489-CCB9A283-22BE-459B-B997-FE3A9B3CDAD3Q36475875-1648A048-F4F4-445A-ADBD-8F69E5F81E6FQ36481945-55BF7C4D-7384-411F-A089-45FAF0F519D9Q36642164-AE0E8379-19F3-49F2-9FCB-D45D3C7F0E26Q36850977-A394D78C-0F5F-462F-A6E2-2ACF4DE3010BQ37098291-6371EF77-9023-4CDE-92D8-00DA11721539Q37656270-632429C4-C6E4-406F-8E58-64611D27D13EQ37796603-3C41C08E-2101-481F-BB87-B885B9D5B8DDQ37817718-0D0C2B8B-C0CA-4D8A-9498-4F70D146EF22Q37898107-14A70081-E262-40C7-82B3-E2B7E7EA413EQ38187679-3D02C2CB-5539-4581-BE10-B881AC537BD8Q38196920-1D959585-7308-4AEA-A3AD-B149CA4F8C70Q38375059-A863FF45-BC43-4ED4-8DB0-111D0F7EA46FQ38470379-F097A76D-BCD8-4B6D-BEAD-463CCE020BACQ38582586-E8CDB89F-3725-4271-8FFB-28EF94D512FDQ38639822-2917E7C0-26CB-4005-88BD-D2CC20F5B609Q38697494-CB76C378-9364-4284-8F94-B54181377F99Q38906896-C82DC08E-B6A3-4035-AE27-A8D4DA0FCEE9Q38943220-45E43672-31F1-43D1-A87C-918F680F5008Q39051797-F6D2E30C-5419-40AC-A11C-9349055BE417Q42242553-66855382-A105-4487-AF4D-3E4FD35FFCF3Q42623499-74BE84D3-94F4-4F9A-89BC-A7F194B32ACAQ45782126-AD9AF69F-C91B-4B20-8ED9-9BC1B5A478BE
P2860
Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Detection of KRAS oncogene in ...... metastatic colorectal cancer.
@en
Detection of KRAS oncogene in ...... metastatic colorectal cancer.
@nl
type
label
Detection of KRAS oncogene in ...... metastatic colorectal cancer.
@en
Detection of KRAS oncogene in ...... metastatic colorectal cancer.
@nl
prefLabel
Detection of KRAS oncogene in ...... metastatic colorectal cancer.
@en
Detection of KRAS oncogene in ...... metastatic colorectal cancer.
@nl
P2093
P921
P1476
Detection of KRAS oncogene in ...... metastatic colorectal cancer.
@en
P2093
Chao-Wen Chen
Chien-Yu Lu
Hsiang-Lin Tsai
Hwei-Ming Wang
Jaw-Yuan Wang
Koung-Shing Chu
Li-Chen Yen
Shiu-Ru Lin
Yu-Tang Chang
Yung-Sung Yeh
P304
P356
10.1158/1078-0432.CCR-08-3179
P407
P577
2009-06-23T00:00:00Z